A congressional probe of Rep. Chris Collins says there is “substantial reason” to believe the Clarence Republican may have been involved in insider trading on an Australian biotech stock, a violation of federal law.
Collins was the largest shareholder of Innate Immunotherapeutics. In a written statement, the congressman says he has followed proper guidelines.
‘Enforcement 40’ for 2020
Join Us On LinkedIn
Join the Securities Litigation and Enforcement Group on LinkedIn